Modality
Cell Therapy
MOA
KIF18Ai
Target
C5
Pathway
JAK/STAT
NASH
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
Phase 2Current
NCT05817394
1,980 pts·NASH
2022-04→TBD·Completed
1,980 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q2
P2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05817394 | Phase 2 | NASH | Completed | 1980 | FEV1 |
Competitors (10)